Effect of different doses of apatinib mesylate combined with chemotherapy on advanced oral cancer

CONCLUSION: Apatinib mesylate (250 mg) combined with chemotherapy can reach optimal efficacy with highest safety but least adverse effects for patients with advanced oral cancer.PMID:35035731 | PMC:PMC8748138

Source: American Journal of Translational Research - January 17, 2022 Category: Research Authors: Wei Yan Jiaxuan Yan Yong Chen Qiang Li Yanjun Guo Source Type: research